ARTV (Artiva Biotherapeutics) Debt-to-Asset : 0.07 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Artiva Biotherapeutics Debt-to-Asset?

Artiva Biotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $3.74 Mil. Artiva Biotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $10.61 Mil. Artiva Biotherapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $209.58 Mil. Artiva Biotherapeutics's debt to asset for the quarter that ended in Dec. 2024 was 0.07.

Artiva Biotherapeutics Debt-to-Asset Historical Data

The historical data trend for Artiva Biotherapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artiva Biotherapeutics Debt-to-Asset Chart

Artiva Biotherapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.07

0.01

0.15

0.16

0.07

Artiva Biotherapeutics Quarterly Data
	Dec19	Dec20	Mar21	Sep21	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial										0.16	0.18	0.21	0.07	0.07

Competitive Comparison of Artiva Biotherapeutics's Debt-to-Asset

For the Biotechnology subindustry, Artiva Biotherapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Artiva Biotherapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artiva Biotherapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Artiva Biotherapeutics's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Artiva Biotherapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Artiva Biotherapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.74	+	10.614)	/	209.581
	=	0.07

Artiva Biotherapeutics's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.74	+	10.614)	/	209.581
	=	0.07

Artiva Biotherapeutics (NAS:ARTV) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Artiva Biotherapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Artiva Biotherapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Artiva Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artiva Biotherapeutics Inc (NAS:ARTV) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

5505 Morehouse Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://www.artivabio.com

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).